Scarica l'app Stockscreener
28.15
2.16%
-0.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$28.77
Aprire:
$29.15
Volume 24 ore:
8.96M
Relative Volume:
0.51
Capitalizzazione di mercato:
$6.57B
Reddito:
$2.35B
Utile/perdita netta:
$128.37M
Rapporto P/E:
53.92
EPS:
0.5221
Flusso di cassa netto:
$57.42M
1 W Prestazione:
-10.89%
1M Prestazione:
-19.91%
6M Prestazione:
+72.70%
1 anno Prestazione:
-40.27%
Intervallo 1D:
$28.11
$29.30
Intervallo di 1 settimana:
$28.11
$32.29
Portata 52W:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
28.15 | 6.99B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | JP Morgan | Overweight |
| 2026-03-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Aggiornamento | Citigroup | Sell → Neutral |
| 2026-03-09 | Aggiornamento | Needham | Hold → Buy |
| 2026-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-01-12 | Iniziato | Evercore ISI | In-line |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Hims & Hers Health (NYSE:HIMS) Upgraded to Hold at Wall Street Zen - MarketBeat
Hims & Hers Health, Inc. • Robinhood Token Price, HIMS Price, Live Charts, and Marketcap - Coinbase
Hims & Hers Health CTO Mohamed Elshenawy Awarded 1.2 Million RSUs - Kalkine Media
Hims & Hers Health Director Christopher D. Payne Awarded 8,768 RSUs in August 2026 - Kalkine Media
Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks - Stocktwits
Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset? - Yahoo Finance
Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop - pluang.com
Hims & Hers Health's Next Act: Making Its Own Drugs Again (NYSE:HIMS) - Seeking Alpha
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: H - The National Law Review
Hims & Hers Health Inc (HIMS) Shares Fall 4.0% -- What GF Score of 78 Tells Investors - GuruFocus
Kaplan Fox is Investigating Hims & Hers Health, Inc. (NYSE: HIMS) for Potential Securities Law Violations - The National Law Review
HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook - Yahoo Finance
HIMS Investigation: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Utah sues Hims over alleged 'subscription trap,' sharing of private health data - St. George News
Securities Fraud Investigation Into Hims & Hers Health, - GlobeNewswire
FTC lawsuit alleges Hims & Hers charged consumers for unwanted prescriptions - Top Class Actions
HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
A Major Telehealth Company Will Sell Longevity Peptides That Clinical Evidence Has Not Yet Backed - Medical Daily
Hims & Hers upgrades women's health app with AI, smart scale integration - TechTarget
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Hims & Hers shared patient health data with Meta, Snap and other advertisers, new class action lawsuit claims - Claim Depot
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm - Morningstar
As Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters
Investigation launched into Hims & Hers for all... - Pluang
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) - marketscreener.com
Hims & Hers’ Revenue Beat Came With a Profitability Problem - MarketBeat
Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health (HIMS) Stock Looks Cheap Even With Legal Risk - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) LawsuitInvestors Urged to Contact Levi & Korsinsky Before August 25, 2025 - The National Law Review
Hims & Hers Health: Algorithmic Transformation of Consumer Healthcare - healthcare.digital
Hims & Hers Q2 Revenue Jumps 38% as International Expansion Accelerates - globalcosmeticsnews.com
HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide - TradingView
Hims & Hers Health, Inc. Signals Aggressive Growth Path - TipRanks
Hims & Hers Health, Inc. (HIMS) Stock forecasts - Yahoo Finance Singapore
A Look at Hims & Hers Health Inc (HIMS) After 4.0% Decline -- GF Value $40.71 vs Price $30.51 - GuruFocus
Hims & Hers planning to sell compounded peptides - The Hill
Hims & Hers Health (NYSE:HIMS) Price Target Cut to $33.00 by Analysts at Citigroup - MarketBeat
FTC Continues Investigation into Hims & Hers Health, Inc. as Lowey Dannenberg Files Class ... - Caledonian Record
FTC Continues Investigation into Hims & Hers Health, Inc. - GlobeNewswire
HIMS Maintained by Morgan Stanley -- Price Target Raised to $28 - GuruFocus
HIMS Maintained by B of A Securities -- Price Target Raised to $32.00 - GuruFocus
HIMS Maintained by Deutsche Bank -- Price Target Raised to $26 - GuruFocus
HIMS Maintains Hold by TD Cowen -- Price Target Raised to $30 - GuruFocus
Bank of America Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $32.23, Implies 1% Upside - TradingView
Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down - Yahoo Finance
Will Hims & Hers’ Higher 2026 Revenue Guidance Amid Rising Losses Change HIMS’s Investment Narrative? - finance.yahoo.com
Hims & Hers Health (NYSE:HIMS) Shares Gap DownTime to Sell? - MarketBeat
Hims & Hers stock trims losses following quarterly results - Yahoo Finance
Hims & Hers Health (HIMS) Faces Profitability Concerns Amid Stro - GuruFocus
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst - Benzinga
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
5.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):